title: Prophylactic use of gabapentin for prevention of succinylcholine-induced fasciculation and myalgia: a randomized, double-blinded, placebo-controlled study.
abstract: BACKGROUND
  Succinylcholine is used for rapid-sequence induction of anesthesia. Fasciculations and myalgia are adverse effects. The pretreatment modalities prevent or minimize its adverse effects.
  
  
  OBJECTIVE
  The present study is designed to evaluate the efficacy of gabapentin on the incidence of fasciculation and succinylcholine-induced myalgia.
  
  
  METHODS
  The study was conducted at a tertiary care teaching hospital in a randomized, double-blinded, placebo-controlled manner.
  
  
  METHODS
  Patients of both genders undergoing laparoscopic cholecystectomy were randomly assigned to two groups. Patients in Group I (Gabapentin group) received 600 mg of gabapentin orally 2 h prior to surgery and patients in Group II (placebo group) received matching placebo. Anesthesia was induced with fentanyl 3 μg/kg, thiopentone 3-5 mg/kg and succinylcholine 1.5 mg/kg. All patients were observed and graded for fasciculations by a blinded observer and patients were intubated. Anesthesia was maintained with oxygen in air, sevoflurane and intermittent vecuronium bromide. After completion of surgery, neuromuscular blockade was reversed. A blinded observer recorded myalgia grade at 24 h. Patients were provided patient-controlled analgesia with fentanyl for postoperative pain relief.
  
  
  METHODS
  Demographic data, fasciculation grade, fentanyl consumption, and myalgia grade were compared using student t test and test of proportions.
  
  
  RESULTS
  The study included 76 American Society of Anesthesiologists' Grade I or II patients of either gender undergoing laparoscopic cholecystectomy. But only 70 patients completed the study. Results demonstrated that the prophylactic use of gabapentin significantly decreases the incidence and the severity of myalgia (20/35 vs. 11/35) (P<0.05) and decreases fentanyl consumption significantly in the study group (620+164 μg vs. 989+238 μg) (P<0.05) without any effects on the incidence and severity of fasciculations.
  
  
  CONCLUSIONS
  Prophylactic use of gabapentin 600 mg in laparoscopic cholecystectomy decreases the incidence and severity of myalgia and fentanyl consumption.
authors.affiliation: Department of Anesthesiology, Institute of Liver and Biliary Sciences, New Delhi, India. ceekeypandey@gmail.com
authors.forename: C K
authors.initials: CK
authors.lastname: Pandey
authors.forename: M
authors.initials: M
authors.lastname: Tripathi
authors.forename: G
authors.initials: G
authors.lastname: Joshi
authors.forename: S T
authors.initials: ST
authors.lastname: Karna
authors.forename: N
authors.initials: N
authors.lastname: Singh
authors.forename: P K
authors.initials: PK
authors.lastname: Singh
mesh_terms: D000328:Adult; D000368:Aged; D000588:Amines / Q000008:administration & dosage*; D016058:Analgesia, Patient-Controlled; D000700:Analgesics / Q000008:administration & dosage*; D000768:Anesthesia, General; D018686:Anesthetics, Intravenous; D017081:Cholecystectomy, Laparoscopic; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage*; D004311:Double-Blind Method; D005207:Fasciculation / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D005260:Female; D000077206:Gabapentin; D006784:Hospitals, Teaching; D006801:Humans; D015994:Incidence; D007194:India / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009467:Neuromuscular Depolarizing Agents / Q000009:adverse effects*; D009468:Neuromuscular Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D010149:Postoperative Pain / Q000139:chemically induced / Q000517:prevention & control*; D012720:Severity of Illness Index; D013390:Succinylcholine / Q000009:adverse effects*; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage*
chemical_list: D000588:Amines; D000700:Analgesics; D018686:Anesthetics, Intravenous; D003509:Cyclohexanecarboxylic Acids; D009467:Neuromuscular Depolarizing Agents; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D013390:Succinylcholine